Humber-QUIPP
Research type
Research Study
Full title
HUMBER QIPP: The Hull Reno-MetaBolic Evaluation & Review Quality Improvement Pharmacist Project. An implementation research that seeks to explore resources and services needed for implementation of a Reno-Metabolic medicines optimisation service.
IRAS ID
351290
Contact name
Sunil Bhandari
Contact email
Sponsor organisation
Hull University Teaching Hospital NHS Trust
Duration of Study in the UK
1 years, 6 months, 2 days
Research summary
Summary:
This clinic is a pharmacist-led-reno-metabolic medicines optimisation clinic. Patients’ medication will be optimised and treatments prescribed to make use of evidence-based medication which slows disease progression. These currently include, but not limited to ACE inhibitors/Angiotensin II receptor antagonists, SGLT2 inhibitors, mineralocorticoid receptor antagonists and potassium binders.
Inclusion criteria:
People between 18 – 80 years with CKD (eGFR >20ml/min/1.73m2) and/or T2DM discharged from the kidney or diabetes wards. Patients on other wards could also be referred by the renal and diabetes specialist team.
Exclusion criteria:
People who cannot commit to clinic attendance (either face-to-face or virtual). People with eGFR < 20ml/min/1.73m2. People with a kidney transplant. People with T1DM. Peolple with polycystic kidney disease.PRIMARY MEASURE:
Medicines implementation spanning classes/approaches to delivering guideline directed medical therapy as directed in the Nice Guidelines for the management of diabetes (NG28) and the CKD management protocol attached.
1. ACEi/ARB
2. SGLT2 inhibitors
3. lipid control/management
4. HbA1c control/diabetes management
5. Non-steroidal mineralocorticoid receptor antagonist
SECONDARY MEASURES:
Patient reported experience measure (PREM).
Emergent observations related to reno-metabolic medicines optimisation care & patient feedback.
Clinical duration per patient (minutes).
Each PDSA cycle collects info on the above to ensure objective and experiential data relating to delivery is captured and informs clinic iterations through the PDSA cycles.Research Outputs:
Research findings gathered through this quality improvement research initiative will be shared in the pharmacy, renal and diabetes departments within the healthcare provider organisation. Data will be presented at national meetings and published in a high impact journal. Education and training sessions will be held for primary care pharmacists with the aim of disseminating core components of high quality reno-metabolic medicines optimisation, translating into improved long-term care for the patient cohort.REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
25/YH/0026
Date of REC Opinion
12 Mar 2025
REC opinion
Further Information Favourable Opinion